- Home
- KGEI vs SAVA Comparison
KGEI vs SAVA Comparison
Compare KGEI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- SAVA
- Stock Information
- Founded
- KGEI 2008
- SAVA 1998
- Country
- KGEI United States
- SAVA United States
- Employees
- KGEI N/A
- SAVA N/A
- Industry
- KGEI
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- SAVA Health Care
- Exchange
- KGEI Nasdaq
- SAVA Nasdaq
- Market Cap
- KGEI 163.1M
- SAVA 157.5M
- IPO Year
- KGEI N/A
- SAVA N/A
- Fundamental
- Price
- KGEI $4.01
- SAVA $2.76
- Analyst Decision
- KGEI Strong Buy
- SAVA Buy
- Analyst Count
- KGEI 1
- SAVA 2
- Target Price
- KGEI $11.00
- SAVA $5.00
- AVG Volume (30 Days)
- KGEI 72.2K
- SAVA 1.3M
- Earning Date
- KGEI 11-12-2025
- SAVA 11-12-2025
- Dividend Yield
- KGEI N/A
- SAVA N/A
- EPS Growth
- KGEI 1.99
- SAVA N/A
- EPS
- KGEI 0.49
- SAVA N/A
- Revenue
- KGEI $60,121,000.00
- SAVA N/A
- Revenue This Year
- KGEI $6.94
- SAVA N/A
- Revenue Next Year
- KGEI $14.53
- SAVA N/A
- P/E Ratio
- KGEI $8.21
- SAVA N/A
- Revenue Growth
- KGEI 10.00
- SAVA N/A
- 52 Week Low
- KGEI $3.34
- SAVA $1.15
- 52 Week High
- KGEI $9.89
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- KGEI 29.87
- SAVA 37.26
- Support Level
- KGEI $3.87
- SAVA $2.79
- Resistance Level
- KGEI $4.28
- SAVA $3.30
- Average True Range (ATR)
- KGEI 0.16
- SAVA 0.22
- MACD
- KGEI 0.01
- SAVA -0.08
- Stochastic Oscillator
- KGEI 21.74
- SAVA 0.47
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.